Trial Profile
A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Cosibelimab (Primary)
- Indications Cancer; Colorectal cancer; Endometrial cancer; Head and neck cancer; Hodgkin's disease; Laryngeal cancer; Malignant melanoma; Merkel cell carcinoma; Mesothelioma; Mouth neoplasm; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pharyngeal neoplasms; Renal cell carcinoma; Skin cancer; Small cell lung cancer; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Sponsors Checkpoint Therapeutics
- 29 Jan 2024 According to a Checkpoint Therapeutics media release, The company plans to resubmit BLA application based on data from this trial.
- 18 Dec 2023 According to a Checkpoint Therapeutics media release, the U.S. Food and Drug Administration has issued a complete response letter for the cosibelimab biologic license application for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.
- 18 Oct 2023 According to a Checkpoint Therapeutics media release, data (n=78) from this study were published in the in the Journal for ImmunoTherapy of Cancer (JITC), the peer-reviewed, online journal of the Society of Immunotherapy of Cancer.